APA (7th ed.) Citation

J, C., Z, Z., H, W., TC, N., GYL, L., S, D., . . . P, W. (2019). Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Oncogene, 38(21), 4125. https://doi.org/10.1038/s41388-019-0708-7

Chicago Style (17th ed.) Citation

J, Cao, et al. "Combining CDK4/6 Inhibition with Taxanes Enhances Anti-tumor Efficacy by Sustained Impairment of PRB-E2F Pathways in Squamous Cell Lung Cancer." Oncogene 38, no. 21 (2019): 4125. https://doi.org/10.1038/s41388-019-0708-7.

MLA (9th ed.) Citation

J, Cao, et al. "Combining CDK4/6 Inhibition with Taxanes Enhances Anti-tumor Efficacy by Sustained Impairment of PRB-E2F Pathways in Squamous Cell Lung Cancer." Oncogene, vol. 38, no. 21, 2019, p. 4125, https://doi.org/10.1038/s41388-019-0708-7.